DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Hematotoxic Effects of Particulate Exposure

Information source: National Institute of Environmental Health Sciences (NIEHS)
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Cancer

Phase: N/A

Status: Completed

Sponsored by: National Institute of Environmental Health Sciences (NIEHS)

Summary

Hematotoxicity is caused by a number of agents such as a benzene by-product called hydroquinone and the antitumor agent doxorubicin. This is a basic research study, conducted using normal human donors, of mechanisms involved in hematotoxicity and of the protective response of human hematopoietic progenitor cells to hematotoxic agents. Tumor necrosis factor exposure protects these cells from a subsequent exposure to hematotoxic agents. The alteration of gene expression in these cells caused by tumor necrosis factor is being studied. Additionally, the tumor necrosis factor-induced biochemical pathways involved in protection of human hematopoietic progenitor cells will be studied.

Clinical Details

Official title: Hematotoxic Effects of Benzene and Doxorubicin

Study design: Allocation: Random Sample

Eligibility

Minimum age: 18 Years. Maximum age: 55 Years. Gender(s): Both.

Criteria:

- healthy

- nonsmoking

- no history of hematologic disorder

- not pregnant

- no medications which suppress hematopoiesis

Locations and Contacts

Additional Information


Last updated: September 1, 2006

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017